Published in Nat Rev Gastroenterol Hepatol on June 07, 2011
The Concise Guide to PHARMACOLOGY 2013/14: enzymes. Br J Pharmacol (2013) 5.57
Aspirin in the chemoprevention of colorectal neoplasia: an overview. Cancer Prev Res (Phila) (2011) 2.03
Aspirin for the prevention of colorectal cancer. Best Pract Res Clin Gastroenterol (2011) 0.96
Rebleeding after initial endoscopic hemostasis in peptic ulcer disease. J Korean Med Sci (2014) 0.91
Prevention and treatment of cancer with aspirin: where do we stand? Semin Oncol (2014) 0.85
Long-Term Low-Dose Aspirin Use Reduces Gastric Cancer Incidence: A Nationwide Cohort Study. Cancer Res Treat (2015) 0.77
Aspirin-induced gastrointestinal damage is associated with an inhibition of epithelial cell autophagy. J Gastroenterol (2015) 0.77
DrugQuest - a text mining workflow for drug association discovery. BMC Bioinformatics (2016) 0.75
Esophageal cancer: The latest on chemoprevention and state of the art therapies. Pharmacol Res (2016) 0.75
Clinical Risk Factors for Gastroduodenal Ulcer in Romanian Low-Dose Aspirin Consumers. Gastroenterol Res Pract (2016) 0.75
Platelet integrin α6β1 controls lung metastasis through direct binding to cancer cell-derived ADAM9. JCI Insight (2016) 0.75
Aspirin use and mortality in two contemporary U.S. cohorts. Epidemiology (2017) 0.75
Cardiovascular events associated with rofecoxib in a colorectal adenoma chemoprevention trial. N Engl J Med (2005) 15.46
Clopidogrel with or without omeprazole in coronary artery disease. N Engl J Med (2010) 7.39
Celecoxib versus omeprazole and diclofenac in patients with osteoarthritis and rheumatoid arthritis (CONDOR): a randomised trial. Lancet (2010) 5.05
A randomized trial of rofecoxib for the chemoprevention of colorectal adenomas. Gastroenterology (2006) 3.35
Cardiovascular events associated with rofecoxib: final analysis of the APPROVe trial. Lancet (2008) 2.83
Low-dose aspirin and cancer mortality: a meta-analysis of randomized trials. Am J Med (2012) 2.23
[Current management of nonvariceal upper gastrointestinal bleeding in Spain]. Gastroenterol Hepatol (2012) 2.04
Efficacy of esomeprazole (20 mg once daily) for reducing the risk of gastroduodenal ulcers associated with continuous use of low-dose aspirin. Am J Gastroenterol (2008) 1.99
Gastric cancer susceptibility is not linked to pro-and anti-inflammatory cytokine gene polymorphisms in whites: a Nationwide Multicenter Study in Spain. Am J Gastroenterol (2007) 1.92
A novel composite endpoint to evaluate the gastrointestinal (GI) effects of nonsteroidal antiinflammatory drugs through the entire GI tract. J Rheumatol (2009) 1.81
Low-dose aspirin affects the small bowel mucosa: results of a pilot study with a multidimensional assessment. Clin Gastroenterol Hepatol (2008) 1.62
Risk of cancer in cases of suspected lynch syndrome without germline mutation. Gastroenterology (2013) 1.55
Adverse effects of non-steroidal anti-inflammatory drugs (NSAIDs, aspirin and coxibs) on upper gastrointestinal tract. Best Pract Res Clin Gastroenterol (2010) 1.51
Risk of advanced proximal neoplasms according to distal colorectal findings: comparison of sigmoidoscopy-based strategies. J Natl Cancer Inst (2013) 1.47
Cardiovascular and upper gastrointestinal bleeding consequences of low-dose acetylsalicylic acid discontinuation. Thromb Haemost (2013) 1.43
Consensus statement on blocking the effects of interleukin-6 and in particular by interleukin-6 receptor inhibition in rheumatoid arthritis and other inflammatory conditions. Ann Rheum Dis (2012) 1.33
Modifiable endoscopic factors that influence the adenoma detection rate in colorectal cancer screening colonoscopies. Gastrointest Endosc (2012) 1.15
Much of the genetic risk of colorectal cancer is likely to be mediated through susceptibility to adenomas. Gastroenterology (2012) 1.15
Consensus development conference on the use of nonsteroidal anti-inflammatory agents, including cyclooxygenase-2 enzyme inhibitors and aspirin. Clin Gastroenterol Hepatol (2006) 1.13
Susceptibility genetic variants associated with colorectal cancer risk correlate with cancer phenotype. Gastroenterology (2010) 1.11
The prevalence of peptic ulcer not related to Helicobacter pylori or non-steroidal anti-inflammatory drug use is negligible in southern Europe. Helicobacter (2004) 1.05
The appropriate use of non-steroidal anti-inflammatory drugs in rheumatic disease: opinions of a multidisciplinary European expert panel. Ann Rheum Dis (2010) 1.02
MLH1 founder mutations with moderate penetrance in Spanish Lynch syndrome families. Cancer Res (2010) 1.01
Nonsteroidal anti-inflammatory drugs and upper and lower gastrointestinal mucosal damage. Arthritis Res Ther (2013) 1.00
Free radicals and antioxidant systems in reflux esophagitis and Barrett's esophagus. World J Gastroenterol (2005) 0.99
Concomitant use of clopidogrel and proton pump inhibitors: impact on platelet function and clinical outcome- a systematic review. Heart (2012) 0.98
Association between achalasia and nitric oxide synthase gene polymorphisms. Am J Gastroenterol (2006) 0.95
Prevention of NSAID-related upper gastrointestinal toxicity: a meta-analysis of traditional NSAIDs with gastroprotection and COX-2 inhibitors. Drug Healthc Patient Saf (2009) 0.94
Editorial: Upper GI bleeding-associated mortality: challenges to improving a resistant outcome. Am J Gastroenterol (2010) 0.93
Factors associated with gastrointestinal perforation in a cohort of patients with rheumatoid arthritis. Arthritis Care Res (Hoboken) (2012) 0.92
Cost-effectiveness of colorectal cancer screening in high-risk Spanish patients: use of a validated model to inform public policy. Cancer Epidemiol Biomarkers Prev (2010) 0.92
Effects of selective PGE2 receptor antagonists in esophageal adenocarcinoma cells derived from Barrett's esophagus. Prostaglandins Other Lipid Mediat (2006) 0.91
Trends in Barrett's esophagus diagnosis in Southern Europe: implications for surveillance. Dis Esophagus (2009) 0.90
[Clinical practice guideline. Prevention of colorectal cancer. 2009 update. Asociación Española de Gastroenterología]. Gastroenterol Hepatol (2009) 0.90
Prevention and Treatment of NSAID Gastropathy. Curr Treat Options Gastroenterol (2014) 0.90
Association of Helicobacter pylori-related distal gastric cancer with the HLA class II gene DQB10602 and cagA strains in a southern European population. Helicobacter (2005) 0.89
Superoxide dismutase prevents development of adenocarcinoma in a rat model of Barrett's esophagus. World J Gastroenterol (2005) 0.88
Myths and facts in the use of anti-inflammatory drugs. Ann Med (2009) 0.88
Barrett's esophagus: natural history. Ann N Y Acad Sci (2011) 0.88
Evidence for endoscopic ulcers as meaningful surrogate endpoint for clinically significant upper gastrointestinal harm. Clin Gastroenterol Hepatol (2009) 0.88
Relevance of GSTM1, GSTT1, and GSTP1 gene polymorphisms to gastric cancer susceptibility and phenotype. Mutagenesis (2012) 0.87
Relevance of IL-1 and TNF gene polymorphisms on interleukin-1beta and tumor necrosis factor-alpha gastric mucosal production. Hum Immunol (2009) 0.87
Managing the adverse effects of nonsteroidal anti-inflammatory drugs. Expert Rev Clin Pharmacol (2011) 0.86
Management of colonic diverticular disease with poorly absorbed antibiotics and other therapies. Therap Adv Gastroenterol (2011) 0.86
Epidemiology and demographics of upper gastrointestinal bleeding: prevalence, incidence, and mortality. Gastrointest Endosc Clin N Am (2011) 0.86
Discovery of specific flavodoxin inhibitors as potential therapeutic agents against Helicobacter pylori infection. ACS Chem Biol (2009) 0.86
CagA-positive Helicobacter pylori infection is not associated with decreased risk of Barrett's esophagus in a population with high H. pylori infection rate. BMC Gastroenterol (2006) 0.84
Gastrointestinal adverse effects of short-term aspirin use: a meta-analysis of published randomized controlled trials. Drugs R D (2013) 0.84
Cyclooxygenase inhibitors decrease the growth and induce regression of human esophageal adenocarcinoma xenografts in nude mice. Int J Oncol (2011) 0.84
Is NSAIDs-related gastrointestinal damage preventable? J Dig Dis (2013) 0.83
Efficacy and safety of piroxicam revisited. A global meta-analysis of randomised clinical trials. Pharmacol Res (2009) 0.83
Role of gastrin-peptides in Barrett's and colorectal carcinogenesis. World J Gastroenterol (2012) 0.81
Genomic rearrangements in MSH2 and MLH1 are rare mutational events in Spanish patients with hereditary nonpolyposis colorectal cancer. Cancer Lett (2005) 0.81
Prognostic role of host cyclooxygenase and cytokine genotypes in a Caucasian cohort of patients with gastric adenocarcinoma. PLoS One (2012) 0.79
Helicobacter pylori and nonmalignant diseases. Helicobacter (2013) 0.79
A case-control study of the association between polymorphisms of the endothelial nitric oxide synthase and glycoprotein IIIa genes and upper gastrointestinal bleeding in users of low-dose aspirin. Clin Ther (2008) 0.78
Optimizing the use of aspirin for cardiovascular prevention. Drugs (2013) 0.78
Cardiac function and aminoterminal pro-brain natriuretic peptide levels in liver-transplanted cirrhotic patients. Clin Transplant (2011) 0.78
Lack of association of IL-12 p40 gene polymorphism with peptic ulcer disease. Hum Immunol (2005) 0.78
Participation and detection rates by age and sex for colonoscopy versus fecal immunochemical testing in colorectal cancer screening. Cancer Causes Control (2014) 0.78
Esomeprazole for prevention and resolution of upper gastrointestinal symptoms in patients treated with low-dose acetylsalicylic acid for cardiovascular protection: the OBERON trial. J Cardiovasc Pharmacol (2013) 0.77
European physicians don't like cytoprotective agents? J Clin Biochem Nutr (2011) 0.77
[The Alliance for the Prevention of Colorectal Cancer in Spain. A civil commitment to society]. Gastroenterol Hepatol (2012) 0.77
Indomethacin but not a selective cyclooxygenase-2 inhibitor inhibits esophageal adenocarcinogenesis in rats. World J Gastroenterol (2012) 0.77
Improving on our goal to reduce NSAID-induced GI complications: a challenging task? Am J Gastroenterol (2008) 0.76
Drug-related damage of the ageing gastrointestinal tract. Best Pract Res Clin Gastroenterol (2009) 0.76
Celecoxib versus diclofenac and omeprazole to prevent recurrent ulcer bleeding. N Engl J Med (2003) 0.75
Compliance with prescriptions of appropriate therapy for nonsteroidal anti-inflammatory drug users: is the glass half empty or half full? Clin Gastroenterol Hepatol (2013) 0.75
Medical Treatment of Diverticular Disease: Antibiotics. J Clin Gastroenterol (2016) 0.75
[Irritable intestine syndrome: a disease with a high social, economic, and health-service load]. Aten Primaria (2006) 0.75
[Gastroprotection in the patient of advanced age: When and how]. Rev Esp Geriatr Gerontol (2012) 0.75
[Gastrointestinal and cardiovascular side effects associated with COX-2 selective inhibitors]. Med Clin (Barc) (2002) 0.75
Atypical and aggressive upper gastrointestinal ulceration associated with aspirin abuse. J Clin Gastroenterol (2002) 0.75
[Screening for adenocarcinoma in Barrett's esophagus: yes or no, when and how?]. Gastroenterol Hepatol (2013) 0.75
Should prophylactic low-dose aspirin therapy be continued in peptic ulcer bleeding? Drugs (2011) 0.75
Reply: High Risk of Gastrointestinal Bleeding on Dual Antiplatelet Treatment. J Am Coll Cardiol (2016) 0.75
[Unmet needs in the approach to irritable bowel syndrome]. Gastroenterol Hepatol (2006) 0.75
Benefits, problems and alternatives to COX-2 inhibition. Curr Top Med Chem (2005) 0.75
[Risk of gastrointestinal bleeding with aspirin and platelet antiaggregants]. Gastroenterol Hepatol (2008) 0.75
Bleeding duodenal ulcer and association with polymorphism of endothelial constitutive nitric oxide synthase gene. Dig Dis Sci (2002) 0.75
[Proton pump inhibitors and clopidogrel in a patient with cardiovascular risk factors: Cardiovascular versus gastrointestinal risk?]. Gastroenterol Hepatol (2009) 0.75
A Balanced View of Efficacy and Safety of Aspirin in Cardiovascular Diseases. Curr Pharm Des (2015) 0.75
Editorial: Harmful and Beneficial Effect of Aspirin on Gastrointestinal Tract. Curr Pharm Des (2015) 0.75
Aspirin: the balance between benefits and harms. Preface. Best Pract Res Clin Gastroenterol (2012) 0.75